Login to Your Account

Financings Roundup

Friday, March 1, 2013
• Dezima Pharma BV, of Naarden, the Netherlands, said it raised €14.2 million (US$18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995), and to develop additional earlier-stage dyslipidemia assets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription